Prøve GULL - Gratis
Recent developments in Bangladesh pharma industry
Chronicle Pharmabiz
|October 30, 2025
Over the past four decades, the pharmaceutical industry in Bangladesh has undergone a sweeping transformation- emerging from its modest, import-dependent roots into a powerful, innovation-driven sector at the forefront of national development. What once relied heavily on foreign suppliers for basic medicines has now evolved into a self-reliant, technologically advanced industry capable of producing everything from lifesaving generics to complex oncology drugs.
Today, the pharmaceutical sector is not just a contributor- it is a cornerstone of Bangladesh's economy, accounting for a significant share of the country's GDP, creating thousands of skilled jobs, and establishing a strong footprint in international markets. With over 98 per cent of domestic pharmaceutical demand met locally and exports reaching more than 150 countries, Bangladesh has firmly positioned itself as a rising global pharma hub.
Backed by forward-thinking policies, the development of an Active Pharmaceutical Ingredients (API) industrial park, and a growing reputation for regulatory compliance, the industry's momentum shows no signs of slowing down. As the world increasingly looks for cost-effective, quality drug manufacturing partners, Bangladesh's pharma sector is stepping confidently into the spotlight- sparking the interest of investors, regulators, and healthcare leaders across the globe.
In this context, exploring the recent developments and future prospects of the Bangladesh pharmaceutical industry reveals not just an economic success story, but a national transformation powered by resilience, ambition, and strategic vision.
Current state of industry
Market size and growth
Bangladesh's pharmaceutical market is currently valued at over US$ three billion and continues to grow at an impressive annual rate of 15-17 per cent. By the end of Q1 2025, the domestic market reached US$ 3.03 billion, reflecting a 17.3 per cent year-on-year increase. The sector now contributes approximately 0.65 per cent to Bangladesh's GDP of US$ 467 billion. In local currency, the market has expanded to over BDT 541 billion, underscoring strong underlying growth despite currency devaluation.
Denne historien er fra October 30, 2025-utgaven av Chronicle Pharmabiz.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Chronicle Pharmabiz
Chronicle Pharmabiz
Recent developments in Bangladesh pharma industry
Over the past four decades, the pharmaceutical industry in Bangladesh has undergone a sweeping transformation- emerging from its modest, import-dependent roots into a powerful, innovation-driven sector at the forefront of national development. What once relied heavily on foreign suppliers for basic medicines has now evolved into a self-reliant, technologically advanced industry capable of producing everything from lifesaving generics to complex oncology drugs.
7 mins
October 30, 2025
Chronicle Pharmabiz
Asia Labex showcases latest advancements in lab technology
DRIVEN by increased investment in pharmaceutical and biotech R&D, a rising need for advanced diagnostic equipment due to disease prevalence, and the growing adoption of automation in labs, the pharma laboratory equipment market has positive prospects.
6 mins
October 30, 2025
Chronicle Pharmabiz
AMMOI demands insurance for Ayurveda day care therapies
THE Ayurvedic Medicine Manufacturers Organ- isation of India (AM- MOI) has sought Union Ayush Minister Prataprao Jadhav's immediate interven- tion to ensure health insurance covers for Ayurvedic day care therapies.
2 mins
October 30, 2025
Chronicle Pharmabiz
Global API market poised for significant changes
The global API market is poised for significant transformation in the coming decade, with growth concentrated in complex APIs, biologics, peptides, and high-potency APIS (HPAPIs).
6 mins
October 30, 2025
Chronicle Pharmabiz
PvPI identifies 16 India specific signals
THE Pharmacovigilance Programme of India (PvPI) under the Indian Pharmacopoeia Commission (IPC) has identified 16 India specific signals. The same has been communicated to the Central Drugs Standard Control Organisation (CDSCO) for timely regulatory interventions towards patient safety.
2 mins
October 30, 2025
Chronicle Pharmabiz
CDSCO sets up digital system to monitor quality of solvents
THE Central Drugs Standard Control Organisation (CDSCO) has set up a Digital Monitoring System on the Online National Drugs Licensing System (ONDLS) portal to monitor the supply chain as well as quality of the high-risk solvents and has asked the State drug controllers to direct all manufacturers of pharma grade solvents to obtain manufacturing license through the portal.
2 mins
October 30, 2025
Chronicle Pharmabiz
Surgicals import grows 11.58%, exports remain stagnant in August
IMPORTS of surgical equipment to the country have reported a decline of 11.58% even as the export of these products was almost stagnant during the month of August, 2025. For the first five months of the current fiscal, imports registered almost 9% growth compared to the same period a year ago.
2 mins
October 30, 2025
Chronicle Pharmabiz
API China focuses on innovation & global co-operation
In recent years, the scale of China's pharmaceutical active pharmaceutical ingredients (APIs) and its global market share have gradually increased. The China API market is experiencing significant growth, driven by expanding global pharmaceutical demand, an aging population, rising chronic disease rates, and the expiration of patents boosting demand for generics.
6 mins
October 30, 2025
Chronicle Pharmabiz
PVPI identifies 16 India specific signals
THE Pharmacovigilance Programme of India (PvPI) under the Indian Pharmacopoeia Commission (IPC) has identified 16 India specific signals. The same has been com- municated to the Central Drugs Standard Control Organisation (CDSCO) for timely regulatory interventions towards patient safety.
2 mins
October 30, 2025
Chronicle Pharmabiz
PM&AC 2025 redefines excellence in pharma manufacturing
THE 7th Annual Pharma Manufacturing & Automation Convention (PM&AC) 2025, co-located with the Pharma Manufacturing & Automation Excellence Awards, concluded on October 8 and 9 at Novotel HICC, Hyderabad, with resounding success.
3 mins
October 30, 2025
Listen
Translate
Change font size
